firstpost_date,url,trackback_author_nick,content,score,trackback_permalink,trackback_author_url
06/12/14,http://twitter.com/onclive/status/476895449459470336,onclive,A phase III trial of ramucirumab for treatment of pts w/ HCC failed to meet its primary endpoint of OS http://t.co/yJlTvMvLw1 #hpbcsm,7.6011066,http://twitter.com/OncLive/status/476895449459470336,http://twitter.com/onclive
06/12/14,http://twitter.com/eungseqconf/status/477091771588300800,eungseqconf,A phase III trial of ramucirumab for treatment of pts w/ HCC failed to meet its primary endpoint of OS http://t.co/FqaHdOcs8P #hpbcsm,7.707378,http://twitter.com/EuNGSeqConf/status/477091771588300800,http://twitter.com/eungseqconf
06/12/14,http://twitter.com/pmedcn/status/477091775665152000,pmedcn,A phase III trial of ramucirumab for treatment of pts w/ HCC failed to meet its primary endpoint of OS http://t.co/riUPRG0ZMJ #hpbcsm,7.706322,http://twitter.com/PMedcn/status/477091775665152000,http://twitter.com/pmedcn
06/13/14,http://twitter.com/targetedonc/status/477426459363901441,targetedonc,Phase III REACH study: Ramucirumab Misses OS Endpoint for Second-Line Treatment of HCC http://t.co/E3HQ9vFE2n #hpbcsm,9.055463,http://twitter.com/TargetedOnc/status/477426459363901441,http://twitter.com/targetedonc
06/13/14,http://twitter.com/cancerassassin1/status/477430697708122114,cancerassassin1,RT @TargetedOnc: Phase III REACH study: Ramucirumab Misses OS Endpoint for Second-Line Treatment of HCC http://t.co/E3HQ9vFE2n #hpbcsm,7.312269,http://twitter.com/cancerassassin1/status/477430697708122114,http://twitter.com/cancerassassin1
06/17/14,http://twitter.com/targetedonc/status/478711184863277056,targetedonc,The Monoclonal Antibody PF-03446962 for HCC http://t.co/g3jivmKwR3 #hpbcsm,7.707439,http://twitter.com/TargetedOnc/status/478711184863277056,http://twitter.com/targetedonc
